41 results about "Antiarrhythmic effect" patented technology

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced by autonomic nervous system tone. The main purpose of this invention was to highlight new findings that have emerged in the study of effects of autonomic nervous system tone on atrial arrhythmias, and its interaction with class III antiarrhythmic drug effects. This invention evaluates the significance of sympathetic and parasympathetic activation by determining the effects of autonomic nervous system using a vagal and stellar ganglions stimulation, and by using autonomic nervous system neurotransmitters infusion (norepinephrine, acetylcholine). This invention evaluates the autonomic nervous system effects on the atrial effective refractory period duration and dispersion, atrial conduction velocity, atrial wavelength duration, excitable gap duration during a stable circuit (such atrial flutter circuit around an anatomical obstacle), and on the susceptibility of occurrence (initiation, maintenance and termination) of atrial re-entrant arrhythmias in canine. This invention also evaluates whether autonomic nervous system activation effects via a local neurotransimitters infusion into the right atria can alter those of class III antiarrhythmic drug, sotalol, during a sustained right atrial flutter. This invention represents an emergent need to set-up and develop a new class of anti-cholinergic drug therapy for the treatment of atrial arrhythmias and to combine this new anti-cholinergic class to antiarrhythmic drugs. Furthermore, this invention also highlights the importance of a local application of parasympathetic neurotransmitters/blockers and a catheter ablation of the area of right atrium with the highest density of parasympathetic fibers innervation. This may significantly reduce the occurrence of atrial arrhythmias and may preserve the antiarrhythmic effects of any drugs used for the treatment of atrial re-entrant arrhythmias.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the left stellate ganglion, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering anti-arrhythmic therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of anti-arrhythmic therapy include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenyloin, carbamazepine, valproate, and phenobarbitone.

The invention relates to stephanine and its pharmaceutically acceptable salt and an application of a solvate for preparing an antiarrhythmic medicine, which belongs to the technical field of medicine. A structural formula of stephanine is shown as a formula (I); the researches on chloroform-induced mice arrhythmia show that stephanine can resist chloroform-induced ventricular fibrillation, preliminary determination is confirmed that the stephanine has antiarrhythmic effect; then barium chloride-induced rat ventricular rhythm test, aconitine intravenous injection-induced rat cardiac rhythm test and rat myocardial ischemia and ischemia reperfusion arrhythmia test are carried out, so that stephanine has good antiarrhythmic effect, and provides a good base for preparing various antiarrhythmic medicines next time.

The invention discloses a novel application of a traditional Chinese medicine extract product-Arctigenin in preparation of anti-arrhythmia medicines. A research found that the Arctigenin has bidirectional anti-arrhythmia effect and can adjust arrhythmia caused by aconitine and ouabain. Arctigenin has an effect for reducing ventricular muscle contraction force. A pharmacological effect of the Arctigenin is bidirectional adjusted cardiac muscle cell inner calcium current, the cardiac muscle cell inner potassium current is increased, and the sodium current is inhibited. The invention shows that the Arctigenin has anti-arrhythmia effect, and especially has bidirectional adjusting on arrhythmia, the side-effect is smaller, the Arctigenin has application prospect for treating toxic arrhythmia and ischemic-reperfusion arrhythmia in aconitine and ouabain; and the Arctigenin with myocardial contractility reduction effect can be taken as an auxiliary treatment measurement for hypertensive disease.

The invention relates to the medicine field, particularly relating to a drug for treating arrhythmia, in particular to an application of Zacopride in preparing a drug for treating the arrhythmia. The invention aims at solving the problems that the present antiarrhythmic drugs have the effect of causing arrhythmia, and IK1 selective agonist has not been discovered at home and abroad so far. The Zacopride is an IK1 selective agonist which is discovered at present for the first time and is used on an antiarrhythmic drug. Used as a drug for treating ischemia-reperfusion arrhythmia, the Zacopride has the similar effect to that of lidocaine, takes effect stably and does not obviously affect the rhythm with wide safety range. In the experiments of arrhythmia induced by ischemia-reperfusion, lidocaine can make the rhythm slower, while the Zacopride has no obvious effect; and when the dosage of the lidocaine is increased by one-third, the antiarrhythmic effect is obviously weakened, while such phenomenon occurs when the Zacopride reaches one hundred times of effective concentration.

The invention relates to a crebanine transdermal patch and a preparation method thereof. The crebanine transdermal patch is formed by sequentially overlapping a back lining layer, a medicine-containing adhesive layer and a protective layer, wherein the medicine-containing adhesive layer is prepared from the following components in parts by weight: 0.03 to 0.135 part of crebanine or crebanine hydrochloride, 0.03 to 0.09 part of cross-linking agent, 0.3 to 0.9 part of pressure sensitive adhesive, 0.19 to 0.63 part of plasticizer, 0.1 to 0.3 part of moisturizer, and 0.007 to 0.206 part of percutaneous penetration enhancer. The crebanine transdermal patch has relatively good percutaneous absorption, is more lasting in action time than that of an oral preparation, is more convenient to use than an injection preparation, is good in compliance of patients, and has the characteristics of security, effectiveness, convenience in using, and no irritation and toxicity. Crebanine in the transdermal patch disclosed by the invention is relatively high in cumulative infiltration capacity and can maintain effective blood drug concentration for a longer time, has obvious and lasting antiarrhythmic effect, and overcomes the phenomena that the lasting time of arrhythmia caused by intravenous injection or gastric infusion administration is relatively short and relapse easily occurs.

The invention relates to actinocongestin gene Sr1 and its coded protein, and also the uses of the said protein in preparation of drugs for cardiovascular disease. The invention employs RT-PCR method, extracts sequence 1 from total RNA of tentacles of sagartia rosea ( sequence 1 indicates) the protein coded by the gene( sequence 2 indicate) Recombinant actinocongestin protein in the invention has cardiac and anti-arrhythmia action, can prepare the cardiovascular disease drugs.

The invention discloses a traditional Chinese medicine preparation for treating arrhythmia. The traditional Chinese medicine preparation consists of the following traditional Chinese medicine raw materials: codonopsis pilosula, valerian, amber powder, panax notoginseng powder, angelica sinensis, fried date kernels, curcuma rcenyujin, ophiopogon japonicas, alisma plantago-aquatica, kudzuvine roots, honey-fried licorice roots, fructus forsythia, cassia twigs, amethyst, acorus calamus, white sandalwood and eupatorium. The medicines are well matched and reasonable in formula, can take the effects of nourishing spleen and tonifying qi, conditioning viscera, clearing heat and removing fire as well as supplementing qi and restoring pulse together, not only is the antiarrhythmic function achieved, but also the function tendency of increasing coronary blood-flow volume, reducing myocardial oxygen consumption and increasing oxygen utilization rate can be achieved, coronary thrombus can be prevented, and the traditional Chinese medicine preparation is an ideal medicine for reducing myocardial ischemia and treating arrhythmia and is worthy of clinical popularization and application.

The invention relates to purposes of polygonum cuspidatum extract, namely polydatin. Myocardial hypertrophy is the most important reason for triggering congestive heart failure. Ventricular hypertrophy usually involves ventricular structure change, namely ventricular remodeling. The ventricular remodeling is a complication of multiple cardiovascular diseases and a vital and decisive element in the development process of the congestive heart failure. The arrhythmia occurrence rate after the myocardial remodeling is increased by 28%, and cardiac sudden deaths caused in the end are increased by over five times. It is indicated that through in vitro study tests, the polydatin remarkably restrains heart ion channels caused by ischemia indury of mice from remodeling and has a great protective effect for arrhythmia, and therefore the polydatin can be used for preparing products resisting against arrhythmia caused by myocardial hypertrophy and/or ventricular hypertrophy. According to the method, the polydatin plays the anti-arrhythmic role by increasing the electric current density of transient outward potassium current (Ito), shortening the action potential duration (APD) of cardiac muscle cells and restraining the QT inter-phase from being prolonged.

The present invention discloses one kind of pinellia tuber extract and its preparation process, medicine composition and use. The pinellia tuber extract is prepared with fresh pinellia tuber, and through air dying, crushing to operate pinellia tuber meal, heat reflux or percolating with organic solvent and/or water for 2-4 times to obtain the extracted liquid, concentrating and drying the extract liquid. The pinellia tuber extract has excellent effects of relieving cough, eliminating phlegm, stopping vomiting, diminishing inflammation, etc. and may be used in treating pneumosilicosis, cough, gastric ulcer, arrhythmia, tumor and other diseases.

The present invention relates to di-benzyl isoquinoline monoether-key alkaloid, isoliensinine, which is extracted from lotus seeds. The present invention also discloses a preparation process of sulfonation. Isoliensinine sodium sulfonate that is prepared through the sulfonation, which not only improves the stability of the phenol alkaloid of isoliensinine, but also improves the water solubility and bioavailability of the isoliensinine. The content of the isoliensinine sodium sulfonate prepared in the method is above 97 percent. Based on the pharmacodynamic results, the method further discloses the anti-arrhythmic security and effectiveness of the isoliensinine sodium sulfonate and preparations thereof.

The invention relates to actinocongestin gene Sr6 and its coded protein, and also the uses of the said protein in preparation of drugs for cardiovascular disease. The invention employs RT-PCR method, extracts sequence 1 from total RNA of tentacles of sagartia rosea ( sequence 1 indicates) the protein coded by the gene( sequence 2 indicates) Recombinant actinocongestin protein in the invention has cardiac and anti-arrhythmia action, can prepare the cardiovascular disease drugs.

The invention provides a low-toxicity anti-arrhythmia medicine and a preparation method thereof. The structure of the compound is shown as a formula I in the specification. Experimental results show that the compound provided by the invention has excellent anti-arrhythmia activity, can delay the VPB latency period of aconitine induced arrhythmia rats and effectively prevent further development of VPB, and the anti-arrhythmia effect of the compound is even superior to that of a positive drug lidocaine under the dosage of 0.30 mg/kg and 0.40 mg/kg. More importantly, compared with bulleyaconitine A, the cardiotoxicity of the compound disclosed by the invention is obviously reduced; compared with the known sand-fried product delta 15, 16-16-demethoxyindinacitine, the compound disclosed by the invention has the advantages that the acute toxicity is obviously lower, and the safety is higher. The invention provides a new choice for preparing a low-toxicity anti-arrhythmia medicine, and provides a new method for controlling the quality of the sand-fried Aconitum bulleyanum or sand-fried Aconitum crassicaule.

The invention relates to actinocongestin gene Sr3 and its coded protein, and also the uses of the said protein in preparation of drugs for cardiovascular disease. The invention employs RT-PCR method, extracts sequence 1 from total RNA of tentacles of sagartia rosea ( sequence 1 indicates) the protein coded by the gene( sequence 2 indicates) Recombinant actinocongestin protein in the invention has cardiac and anti-arrhythmia action, can prepare the cardiovascular disease drugs.

The invention relates to actinocongestin gene Sr7 and its coded protein, and also the uses of the said protein in preparation of drugs for cardiovascular disease. The invention employs RT-PCR method, extracts sequence 1 from total RNA of tentacles of sagartia rosea ( sequence 1 indicates), the protein coded by the gene( sequence 2 indicate). Recombinant actinocongestin protein in the invention has cardiac and anti-arrhythmia action, can prepare the cardiovascular disease drugs.

The invention relates to actinocongestin gene Sr2 and its coded protein, and also the uses of the said protein in preparation of drugs for cardiovascular disease. The invention employs RT-PCR method, extracts sequence 1 from total RNA of tentacles of sagartia rosea ( sequence 1 indicates) the protein coded by the gene( sequence 2 indicates) Recombinant actinocongestin protein in the invention has cardiac and anti-arrhythmia action, can prepare the cardiovascular disease drugs.